Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis  Hidemi Nakagawa, MD, PhD, Osamu Nemoto, MD, PhD, Atsuyuki.

Published byGordon Victor Stokes Modified over 5 years ago

Similar presentations

Presentation on theme: "Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis  Hidemi Nakagawa, MD, PhD, Osamu Nemoto, MD, PhD, Atsuyuki."— Presentation transcript:

1 Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis 
Hidemi Nakagawa, MD, PhD, Osamu Nemoto, MD, PhD, Atsuyuki Igarashi, MD, PhD, Hidehisa Saeki, MD, PhD, Manabu Oda, MS, Kenji Kabashima, MD, PhD, Takeshi Nagata, MS  Journal of Allergy and Clinical Immunology  Volume 144, Issue 6, Pages (December 2019) DOI: /j.jaci Copyright © 2019 The Authors Terms and Conditions

2 Fig 1 Patient disposition.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

3 Fig 2 A, Percentage change from baseline in mEASI score at the EOT (the primary efficacy end point). B, Weekly percentage change in mEASI score over time (least-squares mean [95% CI]). Values obtained after use of rescue medication or prohibited therapies were excluded from analyses of weekly percentage change. *P < .001 vs vehicle. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

4 Fig 3 A, Proportion of patients achieving 50% or greater improvement in mEASI score at the EOT. B, Proportion of patients achieving 75% or greater improvement in mEASI score at the EOT. C, Proportion of patients achieving an IGA score of 0 or 1 at the EOT. D, Proportion of patients achieving an IGA score of 0 or 1 with a 2-point or greater improvement from baseline at the EOT. Error bars represent 95% CIs. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

5 Fig 4 A and B, Weekly change (least-squares mean [95% CI]) from baseline in patient-reported pruritus score over time: daytime score (Fig 4, A) and nighttime score (Fig 4, B). C, Daily change (least-squares mean) from baseline in patient-reported pruritus score over the first week of treatment. D, Weekly change (least-squares mean [95% CI) from baseline in investigator-assessed pruritus score over time. Values obtained after the use of rescue medication or prohibited therapies were excluded from analyses of weekly and daily changes. *P < .001, †P = .002 (0.25% delgocitinib ointment), and ‡P = .001 (0.5% delgocitinib ointment) versus vehicle. D, Daytime; N, nighttime. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

6 Fig E2 Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

Download ppt "Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis  Hidemi Nakagawa, MD, PhD, Osamu Nemoto, MD, PhD, Atsuyuki."

Similar presentations

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.
Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials  Yue Han, MD, Yuxin Chen,
Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis  Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,

Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis  Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,
Jessica P. Hollenbach, PhD, Michelle M. Cloutier, MD 

Jessica P. Hollenbach, PhD, Michelle M. Cloutier, MD 
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Effect of montelukast for treatment of asthma in cigarette smokers

Effect of montelukast for treatment of asthma in cigarette smokers
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 
An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk
Eric D. Bateman, MD, Helen K

Eric D. Bateman, MD, Helen K
Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life  Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life  Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,
Lawrence F. Eichenfield, MD, Lisa Beck, MD 

Lawrence F. Eichenfield, MD, Lisa Beck, MD 
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations  Raymond G.

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations  Raymond G.

Similar presentations

Ads by Google